Insulin resistance is a common feature of obesity and predisposes the affected individuals to a variety of diseases, including hypertension, dyslipidemias, cardiovascular problems and type 2 diabetes mellitus. However, the molecular mechanisms underlying abnormal insulin action and these other pathological states are not well understood. We have been focusing on cytokines, particularly TNFa a and fatty acid binding proteins, as potential sites to study the molecular basis of these disorders. The role of TNFa a in insulin resistance and other pathologies associated with obesity, have been examined in several experimental systems including obese mice with homozygous null mutations at the TNFa a or TNF receptor loci. Analysis of these animals demonstrated that the genetic absence of TNF signaling in obesity: (i) signi®cantly improves insulin receptor signaling capacity and consequently insulin sensitivity; (ii) prevents brown adipose tissue atrophy and b b 3 -adrenoreceptor de®ciency and improves thermo-adaptive responses, (iii) decreases the elevated PAI-1 and TGFb b production; and (iv) lowers hyperlipidemia and hyperleptinemia. Hence, abnormal TNFa a action in adipocytes disturbs many aspects of metabolic homeostasis in obesity.
Introduction
Insulin resistance, a smaller than expected response to a given dose of insulin, is associated with many common diseases including aging, polycystic ovarian disease, syndrome X, cancer, infections, trauma and most signi®cantly obesity and type 2 diabetes.
1,2 The biochemical basis of insulin resistance in type 2 diabetes has been the subject of many studies. Earlier studies have indicated that quantitative regulation of the insulin sensitive glucose transporters (Glut4) and insulin receptors themselves may contribute to this disorder. However, these two factors are probably inadequate to explain the extent of insulin resistance. This point also became apparent by the development of only mild hyperinsulinemia in mice with a targeted mutation in the Glut4 gene. 3 Studies on post-receptor defects in type 2 diabetes have recently focused on the intrinsic catalytic activity of the insulin receptor and downstream signaling events. A reduction in tyrosine phosphorylation of both the insulin receptor (IR) and the insulin receptor substrate-1 (IRS-1) has been noted in both animal and human non-insulin dependant diabetes mellitus (NIDDM). 4, 5 Importantly, this appears to occur in all of the major insulin-sensitive tissues, namely the muscle, fat and liver. It is now clear that decreases in the intrinsic tyrosine kinase activity of the insulin receptor are important components of this disease.
In terms of the site of insulin resistance, much attention has been placed on muscle tissue in systemic insulin resistance, both due to its mass and the fact that defective insulin action is detectable at this site early in the development of type 2 diabetes. Interestingly, recent studies with genetic rodent models have put unexpected weight on the role of adipose tissue and pancreatic islets as dominant sites impacting systemic insulin resistance and development of type 2 diabetes. 6 ± 8 In line with this notion are ®ndings in mice genetically de®cient in aP2, the adipocyte fatty acid-binding protein. The expression of aP2 is highly restricted to differentiated adipocytes. 9 Genetic ablation of aP2 results in substantially increased insulin sensitivity in both dietary and genetic (obaob) model of obesity. 10 Interestingly, studies on this model have also illustrated alteration of signaling between adipocytes and the pancreatic islets, demonstrating that an isolated defect in the lipid biology of adipocytes might have a signi®cant systemic effect on the course of obesity-induced hyperinsulinemia and insulin resistance. 11, 12 Nevertheless, it is still not clear whether adipocyte insulin resistance alone is suf®cient to generate systemic insulin resistance or whether a combination of defects at multiple sites is necessary for the establishment of systemic disease.
Insulin resistance in obesity and the role of TNFa a question in understanding this disease is how obesity can bring about resistance to insulin in the key tissues. It is clear that the molecular etiology of insulin resistance will turn out to be multifactorial where multiple mechanisms contribute to the ®nal phenotype. Several of such molecular targets involved in the inhibition of insulin function andaor receptor signaling have been characterized in the recent years. These include Rad, a potential signaling molecule, which is overexpressed in the muscle tissues of patients with type 2 diabetes, 13 PC-1, an inhibitor of the insulin receptor tyrosine kinase, 14 tumor necrosis factor-a (TNFa) 15, 16 and free fatty acids. 17 Virtually all models of experimental obesity and insulin resistance examined to date seem to produce signi®cantly higher levels of TNFa mRNA and protein compared to their lean counterparts. 18 Neutralization studies in obese rats with a soluble TNF receptor-IgG fusion protein delivered parenterally 15 or by gene transfer 19 have resulted in increased insulin sensitivity, demonstrating the involvement of abnormal TNFa production in the insulin resistance of obesity. Elevated TNFa mRNA and protein expression has also been demonstrated in human obesity. 16 The expression of TNFa was in strong positive correlation with the degree of obesity (body mass index) and the level of hyperinsulinemia and in negative correlation with the adipose tissue lipoprotein lipase activity. Recently, many independent studies have also evaluated circulating TNFa levels in a variety of subjects and have clearly demonstrated increased levels of TNFa protein in obesity andaor insulin resistance syndromes. It is worth noting, however, that in most of these studies the TNFa concentrations were quite low. TNFa expression is also demonstrated in the muscle tissue of obese humans. 20 Expression at this site is also in strong negative correlation with insulin sensitivity. Finally, multiple but not all studies have shown genetic linkage between the TNF locus and adiposity andaor insulin sensitivity. 21 These results indicated that the regulation of TNFa expression in human obesity is very similar to that in rodent models. However, the role of TNFa in human obesity remains to be determined. So far, there has been one attempt to neutralize TNFa in patients with established type 2 diabetes with the use of a single-dose anti-TNFa antibody, which has not resulted in alterations in insulin sensitivity. 22 Clearly, more studies with alternative regimens will be necessary to fully address this issue.
Mechanisms of TNFa a-induced insulin resistance
Several potential mechanisms that might play a role in TNFa-induced insulin resistance have been put forward. Treatment of insulin-responsive cells with TNFa can clearly alter the catalytic activity of the insulin receptor (IR). In a variety of cell types including adipocytes, ®broblasts, hepatoma cells and myeloid 32D cells, TNFa treatment leads to a reduction of insulin-stimulated IR autophosphorylation and subsequent inhibition of IRS-1 phosphorylation without affecting the number of receptors or their insulin binding capacity. 23 ± 26 A similar TNFa-mediated inhibition of the insulin-induced tyrosine phosphorylations is also observed in the muscle and fat tissues of the obese and insulin-resistant faafa rats. 19, 27 Studies with reconstituted systems indicated that the insulin receptor itself is modi®ed or TNFa promotes the production of an inhibitor of the receptor that is associated with these preparations. In support of this, studies have shown that TNFa induces serine phosphorylation of IRS-1 in cultured adipocytes 25 and hepatoma cells 28 and this modi®ed IRS-1 inhibits the signaling capacity of the insulin receptor in vitro. Myeloid 32D cells, which lack endogenous IRS-1, are resistant to the effect of TNFa on IR tyrosine phosphorylation. 25 When IRS-1 is expressed ectopically in these cells, insulin-stimulated IR autophosphorylation becomes very sensitive to TNFa, demonstrating that the presence of IRS-1 is necessary for the inhibition of the IR signaling by TNFa in intact cells. In addition to the cultured cells, a phosphorylation-dependant inhibitory form of IRS-1 is also observed in muscle and fat tissues of obese faafa rats. 25 These results not only provided biochemical and genetic evidence for a novel mechanism by which TNFa induces insulin resistance, but also demonstrated an unexpected role for IRS-1 in the attenuation of the IR signaling. The role of IRS-2 is more complicated. In contrast to IRS-1, IRS-2 appears not to play a signi®cant role in the inhibition of IR signaling by TNFa in cultured 3T3-L1 adipocytes, 29 but appears to play an important role in other cell types such as cultured hepatoma cells 30 and brown adipocytes. 31 Further studies will be needed to de®nitively address the involvement of IRS-2 and possibly additional isoforms in TNF-mediated insulin resistance.
Currently, it is not clear how and through what pathways TNFa stimulates IRS phosphorylation. It has been shown that PKCe can facilitate TNFainduced inhibition of IR signaling in human embryonic kidney (HEK293) cells, whose translocation is stimulated by TNFa. 32 Other PKC isoenzymes, namely a, d b2 and y, have been shown to inhibit IR kinase activity in an IRS-1 dependent manner. 33 TNFa increases intracellular ceramide levels and the treatment of cells with neutral sphingomyelinase and synthetic analogs of ceramides can mimic the actions of TNFa on IR and IRS-1 phosphorylation. 29, 34 It is of course possible that the action of TNFa involves kinase and phosphatase activity of protein tyrosine phosphatases. 26, 35 The relevance of these potential pathways to insulin resistance and type 2 diabetes in vivo is currently under study in several laboratories.
Genetic analysis of the role of TNFa a in obesity and insulin resistance
To investigate the de®nitive role of TNFa in obesityinduced insulin resistance, we have generated obese animals with no functional copy of the TNFa gene. 36 This was accomplished by placing mice homozygous for a targeted null mutation in the TNFa gene (TNFa
7a7
) and their control litter mates (TNFa a ) on a high-fat and high energy diet. On this diet, both TNFa 7a7 and TNFa a mice developed marked obesity but the TNFa 7a7 mice remained highly insulin sensitive as compared to TNFa a animals. For example, fasting hyperinsulinemia became apparent in obese TNFa a mice 4 weeks after the start of the high-fat diet and continued to increase in the following weeks. However, the fasting insulin concentrations in obese TNFa 7a7 mice were signi®-cantly lower than those of the obese TNFa a animals and were indistinguishable from the lean mice, throughout the study. 36 Both insulin and glucose tolerance tests also revealed marked increase in insulin sensitivity in the obese TNFa 7a7 mice compared to obese TNFa a animals. These results clearly demonstrated that TNFa is involved in the insulin resistance associated with dietary obesity. Similar results were obtained from another model of severe obesity induced by gold-thio-glucose (GTG) administration. 37 In an independently generated line of TNFa-de®cient mice, the absence of TNFa also resulted in signi®cant but incomplete increase in insulin sensitivity in GTG-induced obesity. 37 The role of the TNFa-activated pathway of insulin resistance was also tested in a more severe, genetic model of obesity by generating genetically obese mice (obaob) with targeted mutations in both p55 and p75 TNF receptors (TNFRs), effectively abolishing the TNFa signaling and function in these animals. 36 In this experiment the obaob animals developed earlyonset and severe obesity regardless of the TNFR allele they carried. However, fasting plasma glucose and insulin concentrations and glucose and insulin tolerance tests revealed signi®cantly increased insulin sensitivity in the obaob mice lacking TNFa signaling (obaob-p55 7a7 p75 7a7 ) compared to the obaob animals with functional TNFRs. 36 However, the obaob animals that are de®cient in TNFRs were still insulin resistant, indicating that lack of TNF function results in a signi®cant but incomplete protection from the insulin resistance associated with the obaob phenotype. Finally, experiments with the p55 and p75 TNFR-de®cient mice demonstrated that p55 is the predominant mediator of this effect of TNFa. In both dietary and genetic obesity models we did not observe any signi®cant differences between the wildtype and p75 TNFR-de®cient mice. 38 Since in both of these systems the double TNFR-de®ciency had a slightly higher response than p55-de®ciency alone, a complementary role to the action of p55 cannot be ruled out.
Generation of these animal models has been instrumental in understanding the complete biology of TNFa, especially in the context of obesity. In addition to its role in insulin sensitivity, recent studies and preliminary results have shown that TNFa is also the predominant signal for the elevated PAI-1 and TGFb expression 39 and altered brown adipocyte viability in obesity. 40 
Mechanism of TNFa a-induced insulin resistance in obesity
The availability of obese mice genetically de®cient in TNFa function and development of ef®cient neutralization strategies enabled de®nitive examination of the molecular parameters that might contribute to the understanding of TNFa-induced insulin resistance in vivo. These studies demonstrated that the action of TNFa in obesity involves multiple mechanisms. First, the obese TNFa 7a7 mice have lower free fatty acid and leptin levels compared to obese wild-type animals. 36, 41 This reduction in free fatty acids despite signi®cant obesity might be the direct result of the loss of the lipolytic effects of TNFa in adipose tissue or, alternatively, might re¯ect the increased ef®ciency of insulin to suppress lipolysis in the absence of TNFa. However, a similar reduction was not evident in the obaob model. Second, the obese TNFa 7a7 animals had higher Glut4 protein levels in muscle tissue despite the lack of a difference between the muscle Glut4 content of the lean and obese mice. Hence, the increased Glut4 protein levels in TNFa 7a7 animals was not re¯ective of a correction of the Glut4-de®-ciency associated with obesity but rather represented an increase over the quantities observed in muscle tissues of lean mice. Third, the obese TNFa 7a7 animals were signi®cantly spared from obesityinduced de®ciencies in insulin receptor signaling in fat and muscle tissues. Finally, TNFa neutralization in rats resulted in altered phosphatase activity in liver. 19 These observations probably represent the most signi®cant effect of TNFa in generation of obesity-induced insulin resistance due to the critical importance of insulin receptor signaling in biological actions of insulin.
These recent studies with genetic ablation of function clearly demonstrated an important role for TNFa in the insulin resistance of obesity in at least three models of rodent obesity. Many questions are still outstanding. For example, it is still not clear whether adipocyte insulin resistance in general and TNFainduced adipocyte insulin resistance in particular is suf®cient to generate the observed systemic effects in vivo or whether other cells are also involved. Although there is strong data to suggest that TNFa might in¯uence development of cardiovascular disease, its potential role in this or other pathologies associated with obesity has not been directly tested.
These questions will necessitate the development of more complicated genetic models. Molecular components of the cross-talk between insulin and TNF receptors are also not clear. Identi®cation of these molecules will shed light not only on TNF-induced insulin resistance but also on general mechanisms of insulin resistance and diabetes. Finally, it is yet to be determined whether TNFa is involved in the development of insulin resistance or any other obesityrelated pathologies in humans.
